

UNITED STATES EPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 09/802,/09 03/08/01 LAM ARC2865N1 **EXAMINER** HM12/0529 SUSAN K. THOMAS ALZA CORPORATION FAY, Z 950 PAGE MILL ROAD ART UNIT PAPER NUMBER PALO ALTO CA 94303-0802 1614 DATE MAILED: 05/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 09/802,709 Applicant(s)

Lam et al.

Office Action Summary

Examiner

Art Unit 1614

Zohreh Fay -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 2b) X This action is non-final. 2a) This action is **FINAL**. 3) U Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) 💢 Claim(s) 1-34 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) Claim(s) 6) X Claim(s) 1-34 is/are rejected. 7) Claim(s) is/are objected to. are subject to restriction and/or election requirement. 8) U Claims **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on ______ is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 2 20) Other:

Application/Control Number: 09/802,709

Art Unit:

Claims 1-34 are presented for examination.

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-34 are rejected under 35 U.S.C. 103 as being unpatentable over Dong et al. And Patrick et al..

Dong et al. Teach the use of a drug, progesterone in an extended delivery system of multilayers for hormones replacement therapy. See the entire document. Patrick teaches the use of the claimed compound, methylphenidate in an extended release form. See the entire document.

One skilled in the would have been motivated to employ the teaching of the above references, since they in combination relate to the use of a multi layer drug delivery system as old and also to the use of the claimed compounds in a sustained release formulation. The above references in combination make clear that a multi layer drug delivery system is old and well known. To substitue the claimed compounds for the compounds in Dong et al. in a mult-layer composition is within the skill of the artisan in the absence of evidence to the contrary. There is no evidence of record to demonstrate the advantages of claimed specific type of the distribution of the active ingredients or the specific distribution of polymers or secondary components.

Applicant has presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, claims 1-34 are properly rejected under 35 U.S.C. 103.

Art Unit:

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Fay whose telephone number is (703) 308-4604.

ZOHREH FAY PRIMARY EXAMINER GROUP 1200

 $\mathbf{Z}.\mathbf{F}$

May 25, 2001